Rare disease reach Target large undiagnosed patient populations by partnering to expand access to genetic testing and symptom-based screening, leveraging Probably Genetic's rapid diagnosis capability to drive patient funnel for sponsor programs.

Sponsored testing Leverage their no-cost genetic testing programs for neurodegenerative and immunodeficiency conditions to offer sponsor-funded testing opportunities to pharma and advocacy partners seeking to accelerate patient identification.

Clinical partnerships Highlight collaboration history with drug developers and foundations to co-create testing programs, enabling sponsors to embed Probably Genetic in clinical trial recruitment and real-world evidence initiatives.

Tech-enabled scale Position Databricks, cloud-based analytics, and automated workflows as a differentiator for scalable genotype-phenotype mapping, enabling partners to access quality data insights for target discovery and patient stratification.

Market expansion Capitalize on their established partnerships (APBD RF, X4 Pharmaceuticals, SynGAP SRF) to unlock co-marketing and multi-disease campaigns, expanding reach into neurodegenerative, genetic immunodeficiency, and rare disease communities.